← All Signals

🏥 FDA: F.H. INVESTMENTS, Inc. (dba Asteria Health) — Class II

healthcarebearishSource: FDA
90%Confidence
0Views
FDASource
2026-03-03Date

Summary

Second Asteria Health testosterone recall for metal contamination indicates persistent manufacturing issues across product lines. This suggests systemic quality failures that could lead to FDA enforcement actions.

Actionable: Discontinue all Asteria Health testosterone products and initiate supplier qualification for replacement hormones.

AI Confidence: 90%

Data Points

firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productTestosterone, 200 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-1200-43.

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now